Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Core Viewpoint - Tiziana Life Sciences is advancing its lead candidate, intranasal foralumab, as a potential treatment for long COVID by targeting microglial activation, which is linked to persistent brain inflammation and associated symptoms [1][2][5]. Group 1: Company Overview - Tiziana Life Sciences is a biotechnology company focused on developing innovative immunomodulation therapies, with intranasal foralumab being its lead candidate [1][8]. - The company utilizes a unique nasal delivery method for its therapies, which may enhance efficacy and safety compared to traditional intravenous methods [8]. Group 2: Product Development - Foralumab is a fully human anti-CD3 monoclonal antibody that has shown promise in reducing microglial activation in preclinical studies and has been well-tolerated in human trials [1][4][6]. - A previous clinical study demonstrated that intranasal foralumab significantly reduced lung inflammation in patients with mild to moderate COVID-19 [3]. - The company is currently conducting a Phase 2a trial for foralumab in patients with non-active secondary progressive multiple sclerosis, with positive early results reported [6][7]. Group 3: Long COVID Context - Long COVID affects millions globally, characterized by symptoms such as fatigue, cognitive impairment, and psychiatric issues, which are linked to sustained brain inflammation [2]. - The medical community recognizes the urgent need for targeted therapies to address the complexities of long COVID, making Tiziana's approach particularly relevant [5].